Effect of Yikun Neiyi Wan on the Expression of Aromatase P450, COX-2, and ER Related Receptor in Endometrial Cells in Vitro from Patients with Endometriosis

Wang, Qing; Zhao, Hong; Qiu, Xiang; Han, S. W.; Wang, Lingyan; Xu, Bo; Hai, Ju

doi:10.1016/s0254-6272(09)60088-1

Cited by 8 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Endometriosis is a nonmalignant, chronic and common gynecological disease defined as the implantation of endometrium in an abnormal or ectopic location outside the uterus. [1–3] The exact prevalence of endometriosis is unclear. [4] It is estimated that it accounts for about 10% to 15% of women in reproductive age around the world, [5] up to 50% of women with infertility.…”

Section: Introductionmentioning

confidence: 99%

Comparative efficacy and safety of traditional Chinese patent medicine for endometriosis

et al. 2019

View full text Add to dashboard Cite

Background: Endometriosis is a common disease of women of childbearing age. In recent years, the incidence of endometriosis has been on the rise. The main clinical manifestations are pelvic pain and infertility. In recent years, traditional Chinese patent medicine (TCMP) has played an important role in the treatment of endometriosis. So far, there is a lack of comparison among all the current common TCPMs for endometriosis. Consequently, it is indispensable to propose a network meta-analysis (NMA) protocol to discuss the strengths and weaknesses of different TCMPs. Methods: We will comprehensively and systematically retrieve the relevant Chinese and English databases from their inceptions to the May 2019. All randomized controlled trials (RCTs) of TCMPs for Endometriosis will be included. Two researchers will independently screen literature, extract data and assess the risk of bias of included studies. We will conduct pairwise meta-analyses and Bayesian network meta-analyses to assess all the available evidence. Data will be analyzed using STATA and WinBUGS software. Results: This work will compare and rank the relative efficacy of different TCPMs in the treatment of endometriosis in detail. Conclusion: The results of this study will provide reliable evidence for the selection of clinical treatment program and guideline development. PROSPERO registration number: CRD42019127781.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparative efficacy and safety of traditional Chinese patent medicine for endometriosis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…This results in higher rates of amenorrhea and pain-free intervals after just one month of treatment. Gestrinone acts in the endometrium by stimulating the androgen receptors, and the ensuing inhibition of aromatase expression may be a consequence of the reduction in inflammation, since gestrinone has been shown to have no direct effect on aromatase expression in cultured cells from endometriotic cysts [16]. Inflammation plays a pivotal role in the progression of endometriosis [11] and activation of the androgen receptors may represent an alternative for those patients in whom progestin therapy is unsuccessful.…”

Section: Discussionmentioning

confidence: 99%

Effect of vaginal gestrinone in Pentravan® on endometriosis patients using Mirena®: A preliminary report

Maia¹,

Haddad²,

Santos³

et al. 2016

Clin Obstet Gynecol Reprod Med

View full text Add to dashboard Cite

Objective: To investigate the effect of low doses of vaginal gestrinone with oral Pinus pinaster extract and resveratrol on endometriosis-related pain in patients with deep endometriosis using Mirena® and still experiencing symptoms during use of this levonorgestrel-releasing intrauterine system. Patient and methods:This was an open observational study conducted with 20 patients with deep endometriosis and severe pain to investigate the clinical effectiveness of low doses of vaginal gestrinone to improve pain and induce amenorrhea in patients not responding adequately to Mirena®. In Group A (n=14), treatment with vaginal gestrinone, oral Pinus pinaster extract and resveratrol began 3-6 months after Mirena® insertion when it was found that these patients were not responding satisfactorily to treatment. In Group B (n=6), patients initiated treatment with vaginal gestrinone, oral Pinus pinaster extract and resveratrol at the time of Mirena® insertion. The effect of gestrinone on aromatase expression in the eutopic endometrium was also investigated by immunohistochemistry in all patients.

show abstract

“…22Y24 The activity of the enzyme varies considerably between men and women 25 with age, 25,26 menstrual cycle, 27 and weight. 28 In addition, its activity may be influenced by many extrinsic factors, including herbal supplements 29 and calcitriol. 30 Because aromatase is present in many tissues, including adipose tissue, breast, bone, brain, liver, and blood vessels, 22 it is difficult, if not impossible, to assess the overall contribution of this enzyme to systemic drug clearance using in vitro studies conducted in any individual tissue.…”

mentioning

confidence: 99%

Reduced Methadone Clearance During Aromatase Inhibition

Thong²,

Flockhart³

2012

Journal of Clinical Psychopharmacology

View full text Add to dashboard Cite

Methadone is increasingly used in pain management and is a cornerstone in the treatment of opiate withdrawal. It is subject to highly variable clearance among patients. The complete metabolic disposition of methadone is likely to involve a number of enzymes, including specifically CYP2B6. Previous studies in vitro suggest that metabolism by aromatase may also contribute. Single-dose methadone pharmacokinetics (2 mg, intravenous) were studied in 15 healthy postmenopausal women in the presence and absence of a potent aromatase inhibitor, letrozole. A sequential design was used, involving a control period followed by treatment with letrozole (2.5 mg/d, 11 days), in which each subject served as her own control. On average, letrozole treatment reduced methadone systemic clearance by 22% (P = 0.001), increased methadone AUC by 23% (P = 0.007), and increased elimination half-life by 21% (P = 0.042). The plasma parent-to-metabolite ratio also increased (P = 0.009), and there was a linear relationship (R2 = 0.74) between change in this plasma ratio and change in methadone AUC0-∞. In contrast, there was no such association with change in apparent urinary methadone clearance. Letrozole did not change methadone distribution half-life or its volume of distribution. Overall, these data demonstrate a significant decrease in methadone clearance during coadministration of letrozole, consistent with decreased metabolism brought about by aromatase inhibition. An involvement of aromatase in the disposition of methadone may help explain the difficulty in methadone dosing and suggests a broader role for this catalyst of endogenous steroid metabolism in xenobiotic drug disposition.

show abstract

Effect of Yikun Neiyi Wan on the Expression of Aromatase P450, COX-2, and ER Related Receptor in Endometrial Cells in Vitro from Patients with Endometriosis

Cited by 8 publications

References 8 publications

Comparative efficacy and safety of traditional Chinese patent medicine for endometriosis

Comparative efficacy and safety of traditional Chinese patent medicine for endometriosis

Effect of vaginal gestrinone in Pentravan® on endometriosis patients using Mirena®: A preliminary report

Reduced Methadone Clearance During Aromatase Inhibition

Contact Info

Product

Resources

About